Výsledky vyhledávání - "J. G. Cleland"

The control of adrenergic function in heart failure: therapeutic intervention

Autor: A L, Clark, J G, Cleland

Publikováno v: Heart failure reviews. 5(1)

Chronic heart failure is characterised by excess adrenergic activity that augurs a poor prognosis. The reasons for increased adrenergic activity are complex and incompletely understood. The circumstantial evidence relating increased activity to adver

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::5c6fa78e42b794a855a9421df57637e5
https://pubmed.ncbi.nlm.nih.gov/16228919

Zobrazit plný text záznamu

Polypharmacy (or polytherapy) in the treatment of heart failure

Autor: J G, Cleland, A, Baksh, A, Louis

Publikováno v: Heart failure monitor. 1(1)

There is now conclusive evidence that most patients with heart failure due to left ventricular systolic dysfunction should be treated with angiotensin converting enzyme (ACE) inhibitors and beta-blockers. They will also need diuretics for the control

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::4a1bafa1f1a5725107ba8b956b471112
https://pubmed.ncbi.nlm.nih.gov/12634876

Zobrazit plný text záznamu

Cardiovascular critical event pathways for the progression of heart failure; a report from the ATLAS study

Autor: J G, Cleland, K, Thygesen, B F, Uretsky, P, Armstrong, J D, Horowitz, B, Massie, M, Packer, P A, Poole-Wilson, L, Rydén

Publikováno v: European heart journal. 22(17)

Aims To determine the sequence of critical cardiovascular events in the progression of heart failure, and whether aetiology or high-dose vs low-dose lisinopril affected these pathways. Methods and Results This was a post-hoc investigation of the ATLA

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bcb52f5cfa77d463f4b232fee4f4260f
https://pubmed.ncbi.nlm.nih.gov/11492982

Zobrazit plný text záznamu

Toleration of high doses of angiotensin-converting enzyme inhibitors in patients with chronic heart failure: results from the ATLAS trial. The Assessment of Treatment with Lisinopril and Survival

Autor: B M, Massie, P W, Armstrong, J G, Cleland, J D, Horowitz, M, Packer, P A, Poole-Wilson, L, Rydén

Publikováno v: Archives of internal medicine. 161(2)

Treatment with angiotensin-converting enzyme (ACE) inhibitors reduces mortality and morbidity in patients with chronic heart failure (CHF), but most affected patients are not receiving these agents or are being treated with doses lower than those fou

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::0a9848a99708019a6b1b528f11779ad2
https://pubmed.ncbi.nlm.nih.gov/11176729

Zobrazit plný text záznamu

The carvedilol hibernation reversible ischaemia trial; marker of success (CHRISTMAS). The CHRISTMAS Study Steering Committee and Investigators

Autor: J G, Cleland, D, Pennel, S, Ray, G, Murray, P, MacFarlane, A, Cowley, A, Coats, A, Lahiri

Publikováno v: European journal of heart failure. 1(2)

Carvedilol improves left ventricular (LV) function when heart failure is due to LV systolic dysfunction, but the magnitude of the response is heterogeneous among patients with coronary disease, possibly reflecting the presence or volume of hibernatin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::b57227f97316379fbf009c0e0e4480e3
https://pubmed.ncbi.nlm.nih.gov/10937930

Zobrazit plný text záznamu

Update of REACH-1 and MERIT-HF clinical trials in heart failure. Cardio.net Editorial Team

Autor: P, Mylona, J G, Cleland

Publikováno v: European journal of heart failure. 1(2)

This article reviews the design and results of REACH-1 (Research on Endothelin Antagonism in Chronic Heart Failure) and MERIT (Metoprolol controlled and Extended release, Randomised Intervention Trial in congestive Heart Failure), two recently report

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::d377f20dc6871cb54aeea46257437fa5
https://pubmed.ncbi.nlm.nih.gov/10937931

Zobrazit plný text záznamu

Perindopril for elderly people with chronic heart failure: the PEP-CHF study. The PEP investigators

Autor: J G, Cleland, M, Tendera, J, Adamus, N, Freemantle, C S, Gray, M, Lye, D, O'Mahony, L, Polonski, J, Taylor

Publikováno v: European journal of heart failure. 1(3)

The prevalence of chronic heart failure (CHF) rises with increasing age, from1% in those below 65 years of age to5% in those over 65 years of age and is a major cause of morbidity and mortality in older people. Recent European guidelines point to a m

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::7250db8516fe02068142d177ac238b7f
https://pubmed.ncbi.nlm.nih.gov/10960267

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání